Nucleic acids encoding anti-IL-12 antibody
Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.
1. An isolated nucleic acid molecule encoding an anti-IL-12 antibody, comprising a polynucleotide encoding a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:1, a polynucleotide encoding a heavy chain complementarity determining region 2 (CDR2) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:2, a polynucleotide encoding a heavy chain complementarity determining region 3 (CDR3) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:3, a polynucleotide encoding a light chain complementarity determining region 1 (CDR1) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:4, a polynucleotide encoding a light chain complementarity determining region 2 (CDR2) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:5, and a polynucleotide encoding a light chain complementarity determining region 3 (CDR3) comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:6, wherein the antibody is a variant of the antibody comprising the heavy chain CDR1 amino acid sequence of SEQ ID NO:1, the heavy chain CDR2 amino acid sequence of SEQ ID NO:2, the heavy chain CDR3 amino acid sequence of SEQ ID NO:3, the light chain CDR1 amino acid sequence of SEQ ID NO:4, the light chain CDR2 amino acid sequence of SEQ ID NO:5, and the light chain CDR3 amino acid sequence of SEQ ID NO:6.
2. The isolated nucleic acid molecule according to claim 1 , wherein the antibody is human.
3. An isolated nucleic acid vector comprising the isolated nucleic acid molecule according to claim 2 .
4. An isolated host cell comprising the isolated nucleic vector according to claim 3 , wherein the host cell is prokaryotic or eukaryotic.
5. The host cell according to claim 4 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 293, HeLa, P3X63Ag8.653, SP2/0-Ag14, mouse NIH3T3, C127, CV-1, quail QC1-3, mouse L, H9, and Jurkat cells.
6. A method for producing an anti-IL-12 antibody, comprising culturing the isolated host cell of claim 4 under conditions such that the IL-12 antibody is expressed and recovered.
7. A composition comprising the isolated nucleic acid molecule according to claim 1 , and at least one pharmaceutically acceptable carrier or diluent.
8. An isolated nucleic acid molecule encoding an anti-IL-12 antibody, comprising a polynucleotide encoding a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:1, a polynucleotide encoding a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:2, a polynucleotide encoding a heavy chain CDR3 comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:3, a polynucleotide encoding a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:4, a polynucleotide encoding a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a polynucleotide encoding a light chain CDR3 comprising the amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:6.
9. The isolated nucleic acid molecule according to claim 8 , wherein the antibody is human.
10. An isolated nucleic acid vector comprising the isolated nucleic acid molecule according to claim 9 .
11. An isolated host cell comprising the isolated nucleic vector according to claim 10 , wherein the host cell is prokaryotic or eukaryotic.
12. The host cell according to claim 11 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 293, HeLa, P3X63Ag8.653, SP2/0-Ag14, mouse NIH3T3, C127, CV-1, quail QC1-3, mouse L, H9, and Jurkat cells.
13. A method for producing an anti-IL-12 antibody, comprising culturing the isolated host cell of claim 11 under conditions such that the IL-12 antibody is expressed and recovered.
14. A composition comprising the isolated nucleic acid molecule according to claim 8 , and at least one pharmaceutically acceptable carrier or diluent.